regulatory
confidence high
sentiment negative
materiality 0.85
Protagenic Therapeutics receives Nasdaq deficiency notice for failing minimum equity requirement
Protagenic Therapeutics, Inc.new
- Company's stockholders' equity fell below Nasdaq's $2.5M minimum as of March 31, 2024.
- Must submit a compliance plan by July 8, 2024; Nasdaq may grant up to 180-day extension.
- If plan rejected, common stock (PTIX) faces potential delisting; no immediate effect.
- Company exploring collaborations and capital raising to regain compliance.